The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly.
Animesh Dev Pardanani
No relevant relationships to disclose
Jorge E. Cortes
Research Funding - Sanofi
Francisco Cervantes
Consultant or Advisory Role - Novartis; Sanofi
Honoraria - Bristol-Myers Squibb; Novartis
Claire N Harrison
Consultant or Advisory Role - Celgene; Novartis; S*Bio; Sanofi ; YM BioSciences
Honoraria - Celgene; Novartis; S*Bio; Sanofi ; YM BioSciences
Research Funding - Novartis
Expert Testimony - S*Bio
Francesco Passamonti
Consultant or Advisory Role - Celgene; Novartis; Sanofi
Claudia Lebedinsky
Employment or Leadership Position - Sanofi
Frank Neumann
Employment or Leadership Position - Sanofi
Pamela Cohen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Ayalew Tefferi
No relevant relationships to disclose